N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for

A R M Ruhul Amin1, V S Thakur, K Gupta

  • 1Department of Genetics, Case Western Reserve University, Cleveland, OH 44106, USA.

Oncogene
|March 21, 2012
PubMed

Insights

Cancer cells lacking p53 undergo apoptosis when treated with PALA, mediated by TAp73, Noxa, and Bim. Functional p53 protects cells by activating p21, preserving ΔNp73, and inhibiting Noxa/Bim induction.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cellular Signaling

Background:

  • The tumor suppressor p53 is crucial for genomic stability by mediating cellular responses to DNA damage.
  • Disruption of the p53 network is common in human cancers, highlighting the need for understanding p53-dependent and -independent apoptosis.
  • N-(phosphonacetyl)-L-aspartate (PALA) treatment induces DNA damage, leading to differential cellular outcomes based on p53 status.

Purpose of the Study:

  • To investigate the apoptotic signaling pathways activated by PALA treatment.
  • To elucidate the specific role of p53 expression in modulating PALA-induced apoptosis.
  • To identify molecular components involved in both p53-dependent and -independent apoptosis for potential cancer therapies.

Main Methods:

  • Utilized cells with and without functional p53, treated with PALA.
  • Employed dominant-negative plasmids and small interfering RNAs to inactivate specific proteins.
  • Analyzed the expression of key apoptotic regulators including TAp73, ΔNp73, Noxa, Bim, and Bcl-2.

Main Results:

  • PALA induced TAp73, Noxa, and Bim in p53-deficient cells, mediating apoptosis.
  • Functional p53 expression protected cells from PALA-induced apoptosis by upregulating p21, stabilizing ΔNp73, and suppressing Noxa/Bim.
  • PALA treatment inhibited Bcl-2 expression, and its overexpression reduced PALA-induced apoptosis.

Conclusions:

  • Identified opposing roles for p53 and TAp73 in regulating Noxa and Bim induction and apoptosis.
  • Demonstrated that PALA-induced apoptosis in p53-deficient cells is TAp73-dependent.
  • Provided insights for developing strategies to target p53-null cancers while sparing normal cells.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...